Sputum testing provides higher rate of COVID-19 detection

Early and accurate detection is critical for preventing the spread of COVID-19 and providing appropriate care for patients. Nasopharyngeal (NP) swabs, which require inserting a long shaft into the nasal cavity to collect a sample from the back of the nose and throat, are currently the gold standard for collecting a specimen for diagnosis. But the procedure is technically challenging, often uncomfortable for patients and requires personal protective equipment that may be in short supply. Other approaches to collecting specimens — including from an oropharyngeal swab and sputum — have been tested in small studies, but there is uncertainty about which method is best for detecting the virus.

In a new study published in EBioMedicine, investigators from Brigham and Women’s Hospital conducted a systematic review and meta-analysis, analyzing data from more than 3,000 specimens to compare the three approaches. The team found that sputum testing detected the RNA of the virus that causes COVID-19 at significantly higher rates while oropharyngeal swab testing had lower rates. Regardless of the collection method, the earlier samples were collected after symptoms began, the higher the detection rate.

“The accurate diagnosis of COVID-19 has implications for health care, return-to-work, infection control and public health,” said corresponding author Jonathan Li, MD, a faculty member in the Division of Infectious Diseases at the Brigham. “Our gold standard in and out of the hospital is the nasopharyngeal swab, but there’s a lot of confusion about which sampling modality is best and most sensitive. Our study shows that sputum testing resulted in significantly higher rates of SARS-CoV-2 detection and supports the use of this type of testing as a valuable method for the diagnosis and monitoring of COVID-19 patients.”

Li and his colleagues scoured the literature — both preprints and published papers — for studies that assessed at least two respiratory sampling sites using an NP swab, oropharyngeal swab or sputum. From more than 1,000 studies, they identified 11 that met their criteria. These studies included results from a total of 3,442 respiratory tract specimens.

The team examined how often each collection method produced a positive result. For NP swabs, the rate was 54 percent; for oropharyngeal swabs, 43 percent; for sputum, 71 percent. The rate of viral detection was significantly higher in sputum than either oropharyngeal swabs or NP swabs. Detection rates were highest within one week of symptom onset for all three tests.

“When it comes to testing, the earlier the better, as diagnostic accuracy is improved earlier after symptom onset, regardless of the sampling site,” said Li. “Unlike antibody testing, it’s very rare to have a false positive qPCR test when diagnosing COVID-19 early in the course of the disease using these methods.”

Nasopharyngeal swabs are collected through the nasal cavity; oropharyngeal swabs are collected by inserting a shaft through the mouth; and sputum samples are generally collected by having a patient cough deeply to produce and expel phlegm. Not all patients are able to produce a sputum sample; for such patients, a nasopharyngeal swab may be the best collection method. The meta-analysis included only studies conducted on hospitalized individuals — additional study will be needed of patients who are asymptomatic or have mild symptoms. The current study did not assess alternative testing methods, such as saliva or anterior nasal swabs (taken from the front of the nose). Li and his colleagues at the Brigham are currently working on a project, funded by the Massachusetts Consortium on Pathogen Readiness, to collect and process multiple kinds of samples from patients with COVID-19 to create a resource for researchers.

“The holy grail will be to find a test that is readily acceptable by patients, easy to collect, and highly sensitive,” said Li.

This study was funded in part by the National Institutes of Health (U01AI106701) and the Harvard University for AIDS Research (NIAID 5P30AI060354). Li reports personal fees from Abbvie and from Jan Biotech, outside the submitted work. A co-author reports personal fees from Harvard TH Chan School of Public Health, during the conduct of the study, as well as grants from NIH/NIAID, outside the submitted work.

Story Source:

Materials provided by Brigham and Women’s Hospital. Note: Content may be edited for style and length.

Share Button

Health24.com | After heart attack, home care can prevent a return to hospital

Receiving home health care reduces heart attack survivors’ risk of hospital readmission after discharge, a new study finds.

In the United States, only a small percentage of heart attack survivors receive home care such as nursing and physical therapy, according to study authors.

The findings were presented recently at a virtual American Heart Association meeting. Research presented at meetings is typically considered preliminary until published in a peer-reviewed journal.

“Little is known regarding the impact of home health care on heart attack patients,” lead author Muhammad Adil Sheikh said. “Since patients who receive home health care tend to be older and sicker than others, and these characteristics themselves can lead to hospital readmission, we wanted to investigate the impact of home health care alone on readmission.”

Previous health conditions

Sheikh is a clinical assistant professor and hospitalist at the University of Michigan Medical School in Ann Arbor.

He and his team used a national database of hospital readmissions to identify more than 400 000 US heart attack survivors. They included 38 215 (9.4%) who received home health care.

The average age of those who had home health care was 77, compared with 60 for others.

Those who got home care were more likely to have previous health conditions such as diabetes, heart failure, chronic lung or kidney disease, high blood pressure and/or vascular disease.

After adjusting for those conditions, researchers concluded that home health care patients were 11% less likely to be readmitted to a hospital within 30 days of discharge than those who did not have home care.

“Patients who received home health care are older, female or have underlying medical conditions,” Sheikh said in an AHA news release. “These patients are likely to benefit the most from home health care, and this service should be utilised more often to potentially reduce hospital readmission rates.”

Image credit: iStock

Share Button

Heart transplants declined sharply during pandemic

The number of heart transplants in the United States declined sharply during the beginning of the pandemic, even in areas of the country with few COVID-19 cases at the time, according to an analysis by researchers at Columbia University Irving Medical Center.

The study found that the number of heart transplants performed nationwide dropped 26% during the 8-week period marking the height of the pandemic in the Northeast compared to the prior 8 weeks. The drop in transplants was similar across regions and occurred even in areas with lower infection rates.

The study was published in JAMA Cardiology.

“We had concerns that the availability of ICU beds and ventilators would impact our transplant patients, particularly in the Northeast,” says Ersilia DeFilippis, MD, a postdoctoral clinical fellow in medicine and cardiology at Columbia University Vagelos College of Physicians and Surgeons and the first author of the paper.

“But we were surprised to see a decline in heart transplants in other parts of the country, where there were far fewer COVID-19 cases at that time. Our data show that this pandemic has had far-reaching impacts on the care our patients with advanced heart failure are receiving.”

Heart Transplant Patients Require Many Hospital Resources

Heart transplant patients require a lot of hospital resources, DeFilippis says. “Many patients are sick enough to require hospitalization prior to transplant, often in an intensive care unit, sometimes for weeks or months. Some of these patients are supported on temporary machines to help their hearts pump blood to the body. In addition, the transplant surgery itself requires a ventilator, blood products, and significant personnel. Patients then require intensive care unit monitoring in the immediate post-transplant period.”

At the beginning of the pandemic, clinicians had to weigh the risks of exposing medically fragile patients with heart failure, though well enough to remain at home, to SARS-CoV-2 infection with the risks of delaying a life-changing surgery.

DeFilippis and her colleagues found that many clinicians reacted by taking their patients off the waitlist — a measure typically pursued when a patient encounters a health issue that temporarily or permanently disqualifies them for transplantation but was expanded during the pandemic to include patients at risk of SARS-CoV-2 infection and to accommodate transplant centers that deferred acceptance of donor organs due to the pandemic.

They found that waitlist inactivations increased 75% during the pandemic, driven largely by the Northeast. At the same time, 37% fewer people were placed on heart transplant waitlists during the pandemic, with the most significant decreases occurring in the Northeast, the Great Lakes region, and the Southwest.

In addition, the researchers found that the availability of donor hearts decreased by 26% during the COVID-19 period compared with the pre-COVID-19 period.

“It is possible that limited access to testing for donors as well as restrictions on organ procurement organizations may have contributed to the decrease we observed in donor recovery,” says DeFilippis.

Next, the researchers plan to study the impact of these changes on patient survival while on the transplant waitlist and post-transplant survival.

“It will be similarly important to determine how the pandemic has affected the timing of transplant evaluations and changes in left ventricular assist device implantation. As the pandemic continues, we must be mindful of the effects of these delays on our patients,” says DeFilippis.

The paper, “Trends in US Heart Transplant Waitlist Activity and Volume During the COVID-19 Pandemic,” was published in JAMA Cardiology.

The other authors are Lauren Sinnenberg (Brigham and Women’s Hospital and Harvard Medical School, Boston, MA), Nosheen Reza (Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA), Michael M. Givertz (Brigham and Women’s Hospital and Harvard Medical School), Michelle M. Kittleson (Cedars-Sinai Medical Center, Los Angeles, CA), Veli K. Topkara (Columbia University Irving Medical Center, New York, NY), and Maryjane A. Farr (CUIMC).

Share Button

High-deductible health plans and major cardiovascular outcomes

In the first study to examine the association between high out-of-pocket costs and adverse cardiovascular events, research led by the Harvard Pilgrim Health Care Institute finds that individuals with cardiovascular disease risk factors who switched to high-deductible health plans (HDHPs) did not experience increased risk of heart attack or stroke. The study, “Association Between Switching to a High-deductible Health Plan and Major Cardiovascular Outcomes” appears in JAMA Network Open on July 24.

Cardiovascular disease kills more people in the U.S. than any other condition, accounting for 30% of deaths in 2017. Improvements in cardiovascular mortality began slowing a decade ago and major adverse cardiovascular events such as stroke and myocardial infarction began increasing among adults under age 65. Reasons for these trends are unclear, but experts have proposed causes such as the earlier onset of cardiovascular risk factors, stagnation of preventive care, and a change in health insurance coverage in the U.S. Concerns about the contribution of health insurance to these trends are based on the rapid expansion of HDHPs and previous research about health effects of high out-of-pocket costs.

The study team examined the effects of a transition to a HDHP on the risk of major adverse cardiovascular outcomes such as myocardial infarction and stroke. The study population, drawn from a large national health insurance plan, included individuals with risk factors for cardiovascular disease who were continuously enrolled in low-deductible (<$500) health plans during a baseline year followed by up to 4 years in high-deductible (≥$1000) plans after an employer-mandated switch. The matched control group included individuals with the same risk factors who were contemporaneously enrolled in low-deductible plans. The researchers studied time to first major adverse cardiovascular event, defined as stroke or myocardial infarction.

Study findings show that HDHP members did not experience an increase in major adverse cardiovascular events compared with individuals in low-deductible plans. “Based on previous high-deductible health plan research, we had hypothesized that those with risk factors for cardiovascular disease would experience increases in major adverse cardiovascular events after a switch to high-deductible health plans, but this did not turn out to be the case,” said Frank Wharam, lead author and Associate Professor of Population Medicine at the Harvard Pilgrim Health Care Institute and Harvard Medical School. Dr. Wharam adds, “HDHPs typically include features such as low or no out-of-pocket costs for medications and preventive services. Our study detected small changes in cardiovascular medication use and preventive services which may have protected HDHP members from increased adverse cardiovascular events.

These findings provide a measure of reassurance that HDHP enrollment was not associated with an appreciable increased risk of major adverse cardiovascular outcomes. But researchers caution that policymakers and employers should remain careful in promoting HDHPs among low-income and other vulnerable patients given the potential for adverse financial and health outcomes that this study did not address. Research should also extend follow up time to better assess long-term outcomes and should examine whether people with HDHPs ultimately require more intensive workups and more advanced treatments for cardiovascular events.

Story Source:

Materials provided by Harvard Pilgrim Health Care Institute. Note: Content may be edited for style and length.

Share Button

In cell studies, seaweed extract outperforms remdesivir in blocking COVID-19 virus

In a test of antiviral effectiveness against the virus that causes COVID-19, an extract from edible seaweeds substantially outperformed remdesivir, the current standard antiviral used to combat the disease. Heparin, a common blood thinner, and a heparin variant stripped of its anticoagulant properties, performed on par with remdesivir in inhibiting SARS-CoV-2 infection in mammalian cells.

Published online today in Cell Discovery, the research is the latest example of a decoy strategy researchers from the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselear Polytechnic Institute are developing against viruses like the novel coronavirus that spawned the current global health crisis.

The spike protein on the surface of SARS-CoV-2 latches onto the ACE-2 receptor, a molecule on the surface of human cells. Once secured, the virus inserts its own genetic material into the cell, hijacking the cellular machinery to produce replica viruses. But the virus could just as easily be persuaded to lock onto a decoy molecule that offers a similar fit. The neutralized virus would be trapped and eventually degrade naturally.

Previous research has shown this decoy technique works in trapping other viruses, including dengue, Zika, and influenza A.

“We’re learning how to block viral infection, and that is knowledge we are going to need if we want to rapidly confront pandemics,” said Jonathan Dordick, the lead researcher and a professor of chemical and biological engineering at Rensselaer Polytechnic Institute. “The reality is that we don’t have great antivirals. To protect ourselves against future pandemics, we are going to need an arsenal of approaches that we can quickly adapt to emerging viruses.”

The Cell Discovery paper tests antiviral activity in three variants of heparin (heparin, trisulfated heparin, and a non-anticoagulant low molecular weight heparin) and two fucoidans (RPI-27 and RPI-28) extracted from seaweed. All five compounds are long chains of sugar molecules known as sulfated polysaccharides, a structural conformation that the results of a binding study published earlier this month in Antiviral Research suggested as an effective decoy.

The researchers performed a dose response study known as an EC50 — shorthand for the effective concentration of the compound that inhibits 50% of viral infectivity — with each of the five compounds on mammalian cells. For the results of an EC50, which are given in a molar concentration, a lower value signals a more potent compound.

RPI-27 yielded an EC50 value of approximately 83 nanomolar, while a similar previously published and independent in vitro test of remdesivir on the same mammalian cells yielded an EC50 of 770 nanomolar. Heparin yielded an EC50 of 2.1 micromolar, or about one-third as active as remdesivir, and a non-anticoagulant analog of heparin yielded an EC50 of 5.0 micromolar, about one-fifth as active as remdesivir.

A separate test found no cellular toxicity in any of the compounds, even at the highest concentrations tested.

“What interests us is a new way of getting at infection,” said Robert Linhardt, a Rensselaer professor of chemistry and chemical biology who is collaborating with Dordick to develop the decoy strategy. “The current thinking is that the COVID-19 infection starts in the nose, and either of these substances could be the basis for a nasal spray. If you could simply treat the infection early, or even treat before you have the infection, you would have a way of blocking it before it enters the body.”

Dordick added that compounds from seaweed “could serve as a basis for an oral delivery approach to address potential gastrointestinal infection.”

In studying SARS-CoV-2 sequencing data, Dordick and Linhardt recognized several motifs on the structure of the spike protein that promised a fit compatible with heparin, a result borne out in the binding study. The spike protein is heavily encrusted in glycans, an adaptation that protects it from human enzymes which could degrade it, and prepares it to bind with a specific receptor on the cell surface.

“It’s a very complicated mechanism that we quite frankly don’t know all the details about, but we’re getting more information,” said Dordick. “One thing that’s become clear with this study is that the larger the molecule, the better the fit. The more successful compounds are the larger sulfated polysaccharides that offer a greater number of sites on the molecules to trap the virus.”

Molecular modeling based on the binding study revealed sites on the spike protein where the heparin was able to interact, raising the prospects for similar sulfated polysaccharides.

“This exciting research by Professors Dordick and Linhardt is among several ongoing research efforts at CBIS, as well as elsewhere at Rensselaer, to tackle the challenges of the COVID-19 pandemic through novel therapeutic approaches and the repurposing of existing drugs,” said CBIS Director Deepak Vashishth.

“Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro” was published in Cell Discovery with the support of the National Research Foundation of Korea. At Rensselaer, Dordick and Linhardt were joined in the research by Paul S. Kwon, Seok-Joon Kwon, Weihua Jin, Fuming Zhang, and Keith Fraser, and by researchers at the Korea Research Institute of Bioscience and Biotechnology in Cheongju, Republic of Korea, and Zhejiang University of Technology in Hangzhou, China.

Share Button

Study identifies 21 existing drugs that could treat COVID-19

A Nature study authored by a global team of scientists and led by Sumit Chanda, Ph.D., professor at Sanford Burnham Prebys Medical Discovery Institute, has identified 21 existing drugs that stop the replication of SARS-CoV-2, the virus that causes COVID-19.

The scientists analyzed one of the world’s largest collections of known drugs for their ability to block the replication of SARS-CoV-2, and reported 100 molecules with confirmed antiviral activity in laboratory tests. Of these, 21 drugs were determined to be effective at concentrations that could be safely achieved in patients. Notably, four of these compounds were found to work synergistically with remdesivir, a current standard-of-care treatment for COVID-19.

“Remdesivir has proven successful at shortening the recovery time for patients in the hospital, but the drug doesn’t work for everyone who receives it. That’s not good enough,” says Chanda, director of the Immunity and Pathogenesis Program at Sanford Burnham Prebys and senior author of the study. “As infection rates continue to rise in America and around the world, the urgency remains to find affordable, effective, and readily available drugs that can complement the use of remdesivir, as well as drugs that could be given prophylactically or at the first sign of infection on an outpatient basis.”

Extensive testing conducted

In the study, the research team performed extensive testing and validation studies, including evaluating the drugs on human lung biopsies that were infected with the virus, evaluating the drugs for synergies with remdesivir, and establishing dose-response relationships between the drugs and antiviral activity.

Of the 21 drugs that were effective at blocking viral replication, the scientists found:

  • 13 have previously entered clinical trials for other indications and are effective at concentrations, or doses, that could potentially be safely achieved in COVID-19 patients.
  • Two are already FDA approved: astemizole (allergies), clofazamine (leprosy), and remdesivir has received Emergency Use Authorization from the agency (COVID-19).
  • Four worked synergistically with remdesivir, including the chloroquine derivative hanfangchin A (tetrandrine), an antimalarial drug that has reached Phase 3 clinical trials.

“This study significantly expands the possible therapeutic options for COVID-19 patients, especially since many of the molecules already have clinical safety data in humans,” says Chanda. “This report provides the scientific community with a larger arsenal of potential weapons that may help bring the ongoing global pandemic to heel.”

The researchers are currently testing all 21 compounds in small animal models and “mini lungs,” or lung organoids, that mimic human tissue. If these studies are favorable, the team will approach the U.S. Food and Drug Administration (FDA) to discuss a clinical trial(s) evaluating the drugs as treatments for COVID-19.

“Based on our current analysis, clofazimine, hanfangchin A, apilimod and ONO 5334 represent the best near-term options for an effective COVID-19 treatment,” says Chanda. “While some of these drugs are currently in clinical trials for COVID-19, we believe it’s important to pursue additional drug candidates so we have multiple therapeutic options if SARS-CoV-2 becomes drug resistant.”

Screening one of the world’s largest drug libraries

The drugs were first identified by high-throughput screening of more than 12,000 drugs from the ReFRAME drug repurposing collection — the most comprehensive drug repurposing collection of compounds that have been approved by the FDA for other diseases or that have been tested extensively for human safety.

Arnab Chatterjee, Ph.D., vice president of medicinal chemistry at Calibr and co-author on the paper, says ReFRAME was established to tackle areas of urgent unmet medical need, especially neglected tropical diseases. “We realized early in the COVID-19 pandemic that ReFRAME would be an invaluable resource for screening for drugs to repurpose against the novel coronavirus,” says Chatterjee.

The drug screen was completed as rapidly as possible due to Chanda’s partnership with the scientist who discovered the first SARS virus, Kwok-Yung Yuen, M.D., chair of Infectious Diseases at the University of Hong Kong; and Shuofeng Yuan, Ph.D., assistant research professor in the Department of Microbiology at the University of Hong Kong, who had access to the SARS-CoV-2 virus in February 2020.

About the ReFrame library

ReFRAME was created by Calibr, the drug discovery division of Scripps Research, under the leadership of President Peter Shultz, Ph.D., with support from the Bill & Melinda Gates Foundation. It has been distributed broadly to nonprofit collaborators and used to identify repurposing opportunities for a range of disease, including tuberculosis, a parasite called Cryptosporidium and fibrosis.

A global team

The first authors of the study are Laura Riva, Ph.D., a postdoctoral research fellow in the Chanda lab at Sanford Burnham Prebys; and Shuofeng Yuan at the University of Hong Kong, who contributed equally to the study. Additional study authors include Xin Yin, Laura Martin-Sancho, Naoko Matsunaga, Lars Pache, Paul De Jesus, Kristina Herbert, Peter Teriete, Yuan Pu, Courtney Nguyen and Andrey Rubanov of Sanford Burnham Prebys; Jasper Fuk-Woo Chan, Jianli Cao, Vincent Poon, Ko-Yung Sit and Kwok-Yung Yuen of the University of Hong Kong; Sebastian Burgstaller-Muehlbacher, Andrew Su, Mitchell V. Hull, Tu-Trinh Nguyen, Peter G. Schultz and Arnab K. Chatterjee of Scripps Research; Max Chang and Christopher Benner of UC San Diego School of Medicine; Luis Martinez-Sobrido, Wen-Chun Liu, Lisa Miorin, Kris M. White, Jeffrey R. Johnson, Randy Albrecht, Angela Choi, Raveen Rathnasinghe, Michael Schotsaert, Marion Dejosez, Thomas P. Zwaka and Adolfo Garcia-Sastre of the Icahn School of Medicine at Mount Sinai; Ren Sun of UCLA; Kuoyuan Cheng of the National Cancer Institute and the University of Maryland; Eytan Ruppin of the National Cancer Institute; Mackenzie E. Chapman, Emma K. Lendy and Andrew D. Mesecar of Purdue University; and Richard J. Glynne of Inception Therapeutics.

Research reported in this press release was supported by the National Institutes of Health (NIH) (U19AI118610, U19AI135972, HHSN272201700060C, GM132024, HHSN272201400008C, HR0011-19-2-0020, U19AI142733), the Department of Defense (DoD) (W81XWH-20-1-0270), the Bill & Melinda Gates Foundation, Dinah Ruch, Susan and James Blair, Richard Yu and Carol Yu, the Shaw Foundation of Hong Kong, Michael Seak-Kan Tong, May Tam Mak Mei Yin, the Health and Medical Research Fund (COVID190121), the Food and Health Bureau, the Government of the Hong Kong Special Administrative Region; the National Program on Key Research Project of China (2020YFA0707500, 2020YFA0707504), Research Grants Council (T11/707/15), the Huffington Foundation, the JPB Foundation, the Open Philanthropy Project (2020-215611 [5384]) and anonymous donors.

Share Button

If relaxed too soon, physical distancing measures might have been all for naught

If physical distancing measures in the United States are relaxed while there is still no COVID-19 vaccine or treatment and while personal protective equipment remains in short supply, the number of resulting infections could be about the same as if distancing had never been implemented to begin with, according to a UCLA-led team of mathematicians and scientists.

The researchers compared the results of three related mathematical models of disease transmission that they used to analyze data emerging from local and national governments, including one that measures the dynamic reproduction number — the average number of susceptible people infected by one previously infected person. The models all highlight the dangers of relaxing public health measures too soon.

“Distancing efforts that appear to have succeeded in the short term may have little impact on the total number of infections expected over the course of the pandemic,” said lead author Andrea Bertozzi, a distinguished professor of mathematics who holds UCLA’s Betsy Wood Knapp Chair for Innovation and Creativity. “Our mathematical models demonstrate that relaxing these measures in the absence of pharmaceutical interventions may allow the pandemic to reemerge. It’s about reducing contact with other people, and this can be done with PPE as well as distancing.”

The study is published in the journal Proceedings of the National Academy of Sciences and is applicable to both future spikes of COVID-19 and future pandemics, the researchers say.

If distancing and shelter-in-place measures had not been taken in March and April, it is very likely the number of people infected in California, New York and elsewhere would have been dramatically higher, posing a severe burden on hospitals, Bertozzi said. But the total number of infections predicted if these precautions end too soon is similar to the number that would be expected over the course of the pandemic without such measures, she said. In other words, short-term distancing can slow the spread of the disease but may not result in fewer people becoming infected.

Mathematically modeling and forecasting the spread of COVID-19 are critical for effective public health policy, but wide differences in precautionary approaches across the country have made it a challenge, said Bertozzi, who is also a distinguished professor of mechanical and aerospace engineering. Social distancing and wearing face masks reduce the spread of COVID-19, but people in many states are not following distancing guidelines and are not wearing masks — and the number of infections continues to rise.

What are the implications of these findings for policymakers who want to relax social distancing in an effort to revive their economies?

“Policymakers need to be careful,” Bertozzi said. “Our study predicts a surge in cases in California after distancing measures are relaxed. Alternative strategies exist that would allow the economy to ramp up without substantial new infections. Those strategies all involve significant use of PPE and increased testing.”

During the 1918 influenza pandemic, social distancing was first enforced and then relaxed in some areas. Bertozzi points to a study published in Proceedings of the National Academy of Sciences in 2007 that looked at several American cities during that pandemic where a second wave of infections occurred after public health measures were removed too early.

That study found that the timing of public health interventions had a profound influence on the pattern of the second wave of the 1918 pandemic in different cities. Cities that had introduced measures early in the pandemic achieved significant reductions in overall mortality. Larger reductions in peak mortality were achieved by those cities that extended the public health measures for longer. San Francisco, St. Louis, Milwaukee and Kansas City, for instance, had the most effective interventions, reducing transmission rates by 30% to 50%.

“Researchers Martin Bootsma and Neil Ferguson were able to analyze the effectiveness of distancing measures by comparing the data against an estimate for what might have happened had distancing measures not been introduced,” Bertozzi said of the 2007 study. “They considered data from the full pandemic, while we addressed the question of fitting models to early-time data for this pandemic. During the 1918 influenza pandemic, the early relaxation of social distancing measures led to a swift uptick in deaths in some U.S. cities. Our mathematical models help to explain why this effect might occur today.”

The COVID-19 data in the new study are from April 1, 2020, and are publicly available. The study is aimed at scientists who are not experts in epidemiology.

“Epidemiologists are in high demand during a pandemic, and public health officials from local jurisdictions may have a need for help interpreting data,” Bertozzi said. “Scientists with relevant background can be tapped to assist these people.”

Study co-authors are Elisa Franco, a UCLA associate professor of mechanical and aerospace engineering and bioengineering; George Mohler, an associate professor of computer and information science at Indiana University-Purdue University Indianapolis; Martin Short, an associate professor of mathematics at Georgia Tech; and Daniel Sledge, an associate professor of political science at the University of Texas at Arlington.

Share Button

Coronavirus makes changes that cause cells not to recognize it

With an alarm code, we can enter a building without bells going off. It turns out that the SARS coronavirus 2 (SARS-CoV-2) has the same advantage entering cells. It possesses the code to waltz right in.

On July 24 in Nature Communications, researchers at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) reported how the coronavirus achieves this.

The scientists resolved the structure of an enzyme called nsp16, which the virus produces and then uses to modify its messenger RNA cap, said Yogesh Gupta, PhD, the study lead author from the Joe R. and Teresa Lozano Long School of Medicine at UT Health San Antonio.

“It’s a camouflage,” Dr. Gupta said. “Because of the modifications, which fool the cell, the resulting viral messenger RNA is now considered as part of the cell’s own code and not foreign.”

Deciphering the 3D structure of nsp16 paves the way for rational design of antiviral drugs for COVID-19 and other emerging coronavirus infections, Dr. Gupta said. The drugs, new small molecules, would inhibit nsp16 from making the modifications. The immune system would then pounce on the invading virus, recognizing it as foreign.

“Yogesh’s work discovered the 3D structure of a key enzyme of the COVID-19 virus required for its replication and found a pocket in it that can be targeted to inhibit that enzyme. This is a fundamental advance in our understanding of the virus,” said study coauthor Robert Hromas, MD, professor and dean of the Long School of Medicine.

Dr. Gupta is an assistant professor in the Department of Biochemistry and Structural Biology at UT Health San Antonio and is a member of the university’s Greehey Children’s Cancer Research Institute.

In lay terms, messenger RNA can be described as a deliverer of genetic code to worksites that produce proteins.

The laboratory of the lead author, Yogesh Gupta, PhD, is supported through funds from the Max and Minnie Tomerlin Voelcker Foundation, the San Antonio Area Foundation, The University of Texas System, UT Health San Antonio, the Greehey Children’s Cancer Research Institute of UT Health San Antonio, and the Cancer Prevention and Research Institute of Texas (CPRIT).

Story Source:

Materials provided by University of Texas Health Science Center at San Antonio. Note: Content may be edited for style and length.

Share Button

Coronavirus prompts PM into obesity crackdown

Measures to cut obesity are yet to be finalised but could include a ban on junk food TV ads before 21:00.

Share Button

Coronavirus: New face covering rules in force in England

Customers in shops, banks, post offices and takeaways are among those who must now wear masks.

Share Button